All News
More on Methotrexate and ILD Risk
To assess the progression of the interstitial lung disease related to Methotrexate (MTX) exposure, and to evaluate the lung involvement in RA non-ILD patients with MTX exposure, a systematic review was performed to assess whether RA patients receiving methotrexate (MTX) are at greater risk f
IL-1 Inhibition in CPPD
Controlled clinical trials in patients with calcium Pyrophosphate Deposition Disease (CPPD) are scant. Now a metanalysis provides evidence that anakinra, an interleukin-1 inhibitor, is a promising alternative for patients with acute CPPD flares.
Read Article
DAHLIAS study - Nipocalimab in Sjögren's Disease
Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease.
Read Article
PRED-SAFE: Shared Decision-Making Tool for Chronic Prednisone Use
Drs. Jiha Lee and Shivani Garg discuss abstract 1052 (“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic https://t.co/ZBH61Uzzc8
Dr. John Cush RheumNow ( View Tweet)
Learning just got smarter.
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
💡 Educational
🎯 Evidence-based
🧠 Addictive (in a good way)
Try it now and level up your clinical knowledge: https://t.co/oa2wxIRGZv https://t.co/wyZYdabM2G
Links:
Dr. John Cush RheumNow ( View Tweet)
Biologic use in 5008 IBD pts finds higher serious infxn (SIE) rates (vs, RA or PsO). In UC the SIE rate was 5.5/100PY w/ vedolizumab & 7/100PY w/ other biologics. In Crohns the SIE rate was 7.9/100PY w/ vedolizumab vs 6.5/100PY w/ other biologics (adj HR 1.15; 0.95–1.40) (P .16) https://t.co/R7YC220NnO
Dr. John Cush RheumNow ( View Tweet)
Genetic Risks and Severe Cutaneous Reactions to Allopurinol
A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww
Dr. John Cush RheumNow ( View Tweet)
Swedish Birth Registry study of adverse preg outcomes (APOs) after SSc Dx [n=941] or w/in 3 yrs [39] or > 3yrs pre-Dx [839]. SSc women have incr APOs post-Dx, including preeclampsia (RR 3.8), preterm (3.3), C-section (2.5); but also incr APO risk w/in 3 yrs of Dx
Dr. John Cush RheumNow ( View Tweet)
NHANES study of 4,622 adults, including 296 w/ RA, shows volatile organic compounds (VOCs) & metabolites (mVOCs) exposures increases the risk of #RA (OR: 1.23 - 1.37), especially in females. https://t.co/pBNLTRkyLn https://t.co/L6nVbYlBhD
Dr. John Cush RheumNow ( View Tweet)
#ACR25 PsA Topic Panel
A focused conversation on the latest in psoriatic arthritis care - from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping PsA practice right now. https://t.co/PP0fkweXsZ
Dr. John Cush RheumNow ( View Tweet)
New Approaches to Therapy in PsA
Dr. Arthur Kavanaugh offers an overview of new approaches to therapy in psoriatic arthritis, at #ACR25.
https://t.co/9vHgQ6S2JD https://t.co/5mvX1rOrIP
Links:
Dr. John Cush RheumNow ( View Tweet)
Why I love the late breaking abstracts
https://t.co/jCSfNOoFeT https://t.co/uZWSm9SQAI
Dr. John Cush RheumNow ( View Tweet)
Tuesday Nite Rheumatology (on 11.11.25) https://t.co/xk8NOwLN7z
Links:
Dr. John Cush RheumNow ( View Tweet)
The Interview (11.7.2025)
I've conducted thousands of interviews, mainly for medical school admissions and medical or research jobs. They're all similar, with me seeking the "right one" and interviewees feeling apprehensive, uncertain, and hopeful. My extensive experience has https://t.co/KZzfEKx4qm
Dr. John Cush RheumNow ( View Tweet)
Late-Breaking Trials in axSpA and PsA
https://t.co/EWeF0nkb1h https://t.co/HgY0be0PDX
Dr. John Cush RheumNow ( View Tweet)
Diagnostic Delays in PsA: A Radiographic Perspective
Dr. Brian Jaros reports on abstract 1713 (Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients), presented at #ACR25. https://t.co/iLllm7DcCF
Dr. John Cush RheumNow ( View Tweet)
S.Korean study of 481 pts w/ myositis (IIM) - 12.9% (n = 62) had myositis-assoc. cancer. CA risk factos= older age, male, current smoking, dermatomyositis, TIF1γ; but lower risk w/ anti-synthetase synd, overlap myositis, arthritis, & ILD. SCRIM score had AUROC = 0.852 https://t.co/MdU1fRWWgS
Dr. John Cush RheumNow ( View Tweet)
Genentech announced positive results from the phase III DBRPCT ALLEGORY trial showin safety & efficacy of obinutuzumab in ~300 SLE pts on SOC. Results have yet to be presented publicly. https://t.co/4hoT9dBtPq
Dr. John Cush RheumNow ( View Tweet)
Tapering in SELECT GCA: Steroids are the Problem
Dr. Mike Putman reports on abstract 0895 (Impact of Glucocorticoid Tapering in Giant Cell Arteritis: Analysis From the SELECT-GCA Trial) presented at #ACR25.
https://t.co/80Bl49uImB https://t.co/GjlHHjPW2u
Links:
Dr. John Cush RheumNow ( View Tweet)
Systematic review of 10 studies showed TNFi exposure in utero not assoc w/ incr risk of infant severe infxn (4 RCTs); same for breast milk exposure (2 RCTs).
Infant vaccination outcomes unaffected by TNFi use, but rec delaying BCG vaccination if TNFi exposed https://t.co/02Nn6TuzR3
Dr. John Cush RheumNow ( View Tweet)
